All Stories

  1. Modulating chitosan-PLGA nanoparticle properties to design a co-delivery platform for glioblastoma therapy intended for nose-to-brain route
  2. The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications
  3. The metabolic landscape of urological cancers: New therapeutic perspectives
  4. Microbes and Cancer: Friends or Faux?
  5. IL-17A and IL-17F orchestrate macrophages to promote lung cancer
  6. Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy
  7. A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems
  8. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy
  9. Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
  10. Lactate and Lactate Transporters as Key Players in the Maintenance of the Warburg Effect
  11. New horizons on pH regulators as cancer biomarkers and targets for pharmacological intervention
  12. Fucoidan from Fucus vesiculosus inhibits new blood vessel formation and breast tumor growth in vivo
  13. Magnetoliposomes Containing Calcium Ferrite Nanoparticles for Applications in Breast Cancer Therapy
  14. Direct actions of adiponectin on changes in reproductive, metabolic, and anti-oxidative enzymes status in the testis of adult mice
  15. Rational Identification of a Colorectal Cancer Targeting Peptide through Phage Display
  16. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma
  17. Role of adiponectin as a modulator of testicular function during aging in mice
  18. Synthesis, characterization and in vitro validation of a magnetic zeolite nanocomposite with T2-MRI properties towards theranostic applications
  19. Photodynamic Therapy at Low-Light Fluence Rate: in vitro Assays on Colon Cancer Cells
  20. Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment
  21. Adenine Derivatives: Promising Candidates for Breast Cancer Treatment
  22. Bioenergetic modulators hamper cancer cell viability and enhance response to chemotherapy
  23. The clinicopathological significance of monocarboxylate transporters in testicular germ cell tumors
  24. Internalization studies on zeolite nanoparticles using human cells
  25. Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells
  26. Impact of mesenchymal stem cells’ secretome on glioblastoma pathophysiology
  27. Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy
  28. Monocarboxylate transporter 1 is a key player in glioma-endothelial cell crosstalk
  29. GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior
  30. Value of pH regulators in the diagnosis, prognosis and treatment of cancer
  31. Comparison of different silica microporous structures as drug delivery systems for in vitro models of solid tumors
  32. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors
  33. Characterization of acetate transport in colorectal cancer cells and potential therapeutic implications
  34. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation
  35. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis
  36. The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside
  37. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas
  38. Prognostic significance of monocarboxylate transporter expression in oral cavity tumors
  39. Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
  40. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4
  41. Absence of microsatellite instability andBRAF(V600E) mutation in testicular germ cell tumors
  42. Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness
  43. Colon Cancer Chemoprevention by Sage Tea Drinking: Decreased DNA Damage and Cell Proliferation
  44. Targeting Metabolic Reprogramming as an Anti- Cancer Strategy: Aiming at Monocarboxylate Transporters
  45. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors
  46. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors
  47. Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas
  48. Glucose addiction in cancer therapy: advances and drawbacks
  49. Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells
  50. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy
  51. Abstract B24: Natural withanolides: A new group of anticancer drugs that selectively target the PI3K-mTOR pathway as novel potent therapeutics against colon cancers in vitro and in vivo
  52. Cathepsin D protects colorectal cancer cells from acetate-induced apoptosis through autophagy-independent degradation of damaged mitochondria
  53. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3
  54. The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH
  55. Brain Tumor Metabolism — Unraveling Its Role in Finding New Therapeutic Targets
  56. Impact of an Educational Hands-on Project on the Antimicrobial, Antitumor and Anti-Inflammatory Properties of Plants on Portuguese Students’ Awareness, Knowledge, and Competences
  57. Micro- and Mesoporous Structures as Drug Delivery Carriers for Salicylic Acid
  58. Localization of MCT 2 at peroxisomes is associated with malignant transformation in prostate cancer
  59. In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma
  60. Urothelial bladder cancer progression: lessons learned from the bench
  61. Evolving hallmarks in urothelial bladder cancer: unveiling potential biomarkers
  62. Propolis: A Complex Natural Product with a Plethora of Biological Activities That Can Be Explored for Drug Development
  63. Antitumoural and antiangiogenic activity of Portuguese propolis in in vitro and in vivo models
  64. Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
  65. Lactate transporters and vascular factors in HPV-induced squamous cell carcinoma of the uterine cervix
  66. The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype
  67. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance
  68. T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
  69. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer
  70. Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization
  71. Characterization of monocarboxylate transporter activity in hepatocellular carcinoma
  72. Gene Disruption Using Zinc Finger Nuclease Technology
  73. Potentiation of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma
  74. Differential sensitivities to lactate transport inhibitors of breast cancer cell lines
  75. Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: Key events in the progression from an in situ to an invasive breast carcinoma
  76. Portuguese propolis disturbs glycolytic metabolism of human colorectal cancer in vitro
  77. Assessing the Impact of a School Intervention to Promote Students’ Knowledge and Practices on Correct Antibiotic Use
  78. Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin
  79. Contribution of Monocarboxylate Transporters to the Aggressive Phenotype of Breast Cancer
  80. NIR Triggered Upconversion Nanoparticle Based Drug Delivery Systems for Photodynamic Therapy
  81. A Hospital Based Cohort Study of Colorectal Cancer Cases Treated at Braga Hospital, Northern Portugal
  82. The Monocarboxylate Transporter Inhibitor α-Cyano-4-Hydroxycinnamic Acid Disrupts Rat Lung Branching
  83. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets
  84. Zeolite Structures Loading with an Anticancer Compound As Drug Delivery Systems
  85. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer
  86. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma
  87. Lactate-Induced IL-8 Pathway in Endothelial Cells--Letter
  88. Role of monocarboxylate transporters in human cancers: state of the art
  89. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate
  90. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs)
  91. CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis
  92. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer
  93. Encapsulation of α-cyano-4-hydroxycinnamic acid into a NaY zeolite
  94. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies
  95. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma
  96. The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
  97. Expression of Monocarboxylate Transporters 1, 2, and 4 in Human Tumours and Their Association with CD147 and CD44
  98. Portuguese students' knowledge of antibiotics: a cross-sectional study of secondary school and university students in Braga
  99. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer
  100. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma
  101. Increasing Expression of Monocarboxylate Transporters 1 and 4 Along Progression to Invasive Cervical Carcinoma
  102. 378 POSTER CD147 expression correlates with monocarboxylate transporters 1 and 4 in cervical carcinoma
  103. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer
  104. Induction of COX-2 expression by acrolein in the rat model of hemorrhagic cystitis
  105. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas
  106. A New Model of Laryngitis: Neuropeptide, Cyclooxygenase, and Cytokine Profile
  107. Peritumoural, but not intratumoural, lymphatic vessel density and invasion correlate with colorectal carcinoma poor-outcome markers
  108. Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix
  109. Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats
  110. Cyclooxygenase-2 and Epidermal Growth Factor Receptor Expressions in Different Histological Subtypes of Cervical Carcinomas
  111. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma
  112. Functional Purification of the Monocarboxylate Transporter of the Yeast Candida utilis
  113. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
  114. Functional expression of the lactate permease Jen1p of Saccharomyces cerevisiae in Pichia pastoris
  115. l–[U–14C]Lactate binding to a 43 kDa protein in plasma membranes of Candida utilis